Skip to main content
. Author manuscript; available in PMC: 2024 Apr 10.
Published in final edited form as: Ann Rheum Dis. 2022 Sep 15;82(2):262–271. doi: 10.1136/ard-2021-221269

Figure 4. Panobinostat effects on human meniscus cells and synoviocytes.

Figure 4.

Human OA meniscus cells at passage 1 from 6 donors (Panel A) and OA synoviocytes at passage 1 from 6 donors (Panel B) were treated with Panobinostat for 24 h when IL-1β (1 ng/ml) was added for additional 6 h and RNA was isolated for RT-qPCR analysis.

***= p<0.001; **= p<0.01; *= p<0.05